Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Lymphoma

Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A

Leukemia volume 14, pages 898–904 (2000)Cite this article

Abstract

In the present study, we analysed 34 de novo diffuse large B cell lymphoma (DLCL) from a population-based lymphoma registry for alterations of the RB1 pathway at the genetic (RB1 and CDK4) and protein (pRb, cyclin D1, cyclin D3, CDK4, and E2F-1) level. The results were correlated with the data from our previous studies of CDKN2A deletion and hypermethylation, other p53 pathway components, p27Kip1 expression, and proliferation, as well as with clinical outcome, including prognosis. We found aberrant pRb expression in four (12%) of 34 DLCLs. One of these had a point mutation in intron 3 10 bp downstream of exon 3 generating a novel splice signal. Seven tumours (21%) showed cyclin D3 overexpression, including all three thyroid lymphomas (P = 0.006). Cyclin D3 overexpression and p16INK4A/pRb aberrations were mutually exclusive, supporting an oncogenic role for cyclin D3 in DLCL. p16INK4A inactivation, cyclin D3 overexpression, or aberrant pRb expression was identified in 18 of 34 DLCLs (53%). Combining these results with our previous p53 pathway studies showed that 82% of the de novoDLCLs had alterations of these pathways, and that both pathways were altered in 13 cases (38%). Low E2F-1 expression was associated with treatment failure (P = 0.020), and multivariate analysis of overall survival identified both low E2F-1 expression (relative risk = 6.9; P = 0.0037) and p16INK4Ainactivation (relative risk = 3.3; P = 0.0247) as independent prognostic markers. These data support a role of E2F-1 as tumour suppressor gene in lymphoma and strongly suggest that the RB1 and p53 pathways are important in the development of de novo DLCL. Furthermore, low E2F-1 expression and p16INK4A inactivation may serve as prognostic markers for patients with this type of lymphoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Sherr CJ . Cancer cell cycles Science 1996 274: 1672–1677

    Article  CAS  PubMed  Google Scholar 

  2. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR . The E2F transcription factor is a cellular target for the RB protein Cell 1991 65: 1053–1061

    Article  CAS  PubMed  Google Scholar 

  3. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J-Y, Livingston DM . Functional interactions of the retinoblastoma protein with mammalian D-type cyclins Cell 1993 73: 487–497

    Article  CAS  PubMed  Google Scholar 

  4. Serrano M, Hannon GJ, Beach D . A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 Nature 1993 366: 704–707

    Article  CAS  PubMed  Google Scholar 

  5. Polyak K, Kato J-Y, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A . p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest Genes Dev 1994 8: 9–22

    Article  CAS  PubMed  Google Scholar 

  6. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ . Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB Oncogene 1994 9: 3375–3378

    CAS  PubMed  Google Scholar 

  7. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN . CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated Cancer Res 1996 56: 150–153

    CAS  PubMed  Google Scholar 

  8. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS III, James CD . CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines Cancer Res 1994 54: 5804–5807

    CAS  PubMed  Google Scholar 

  9. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH . p14ARF links the tumour suppressors RB and p53 Nature 1998 395: 124–125

    Article  CAS  PubMed  Google Scholar 

  10. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA . The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 Cell 1998 92: 713–723

    Article  CAS  PubMed  Google Scholar 

  11. Wingo PA, Ries LAG, Giovino GA, Miller DS, Rosenberg HM, Shopland DR, Thun MJ, Edwards BK . Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking J Natl Cancer Inst 1999 91: 675–690

    Article  CAS  PubMed  Google Scholar 

  12. Chan WC, Armitage JO, Gascoyne R, Connors J, Close P, Jacobs P, Norton A, Lister TA, Pedrinis E, Cavalli F, Berger F, Coiffier B, Ho F, Liang R, Schauer A, Hiddemann W, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Weisenburger DD, Harris NL, Anderson JR, Roy P . A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma Blood 1997 89: 3909–3918

    Google Scholar 

  13. Ries LAG, Kosary CL, Hankey BF, Miller BA, Edwards BK . SEER Cancer Statistics Review, 1973–1996 National Cancer Institute: Bethesda 1999

    Google Scholar 

  14. Offit K, Chaganti RSK . Chromosomal aberrations in non-Hodgkin's lymphoma. Biologic and clinical correlations Hematol Oncol Clin North Am 1991 5: 853–869

    Article  CAS  PubMed  Google Scholar 

  15. Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RSK, Dalla-Favera R . Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma Science 1993 262: 747–750

    Article  CAS  PubMed  Google Scholar 

  16. Møller MB, Ino Y, Gerdes A-M, Skjødt K, Louis DN, Pedersen NT . Aberrations of the p53 pathway components p53, MDM2, and CDKN2A appear independent in diffuse large B cell lymphoma Leukemia 1999 13: 453–459

    Article  PubMed  Google Scholar 

  17. Møller MB, Skjødt K, Mortensen LS, Pedersen NT . Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1 Br J Haematol 1999 105: 730–736

    Article  PubMed  Google Scholar 

  18. Møller MB, Gerdes A-M, Skjødt K, Mortensen LS, Pedersen NT . Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma Clin Cancer Res 1999 5: 1085–1091

    PubMed  Google Scholar 

  19. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Müller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA . A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood 1994 84: 1361–1392

    CAS  PubMed  Google Scholar 

  20. Møller MB, d'Amore F, Christensen BE . Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis Eur J Cancer 1994 30A: 1760–1764

    Article  PubMed  Google Scholar 

  21. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, Cabanillas F, Canellos GP, Coiffier B, Connors JM, Cowan RA, Crowther D, Dahlberg S, Engelhard M, Fisher RI, Gisselbrecht C, Horning SJ, Lepage E, Lister TA, Meerwald JH, Montserrat E, Nissen NI, Oken MM, Peterson BA, Tondini C, Velasquez WA, Yeap BY . A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project New Engl J Med 1993 329: 987–994

    Article  Google Scholar 

  22. Zukerberg LR, Benedict WF, Arnold A, Dyson N, Harlow E, Harris NL . Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1 Blood 1996 88: 268–276

    CAS  PubMed  Google Scholar 

  23. Doglioni C, Chiarelli C, Macri E, Dei Tos AP, Meggiolaro E, Dalla Palma P, Barbareschi M . Cyclin D3 expression in normal, reactive and neoplastic tissues J Pathol 1998 185: 159–166

    Article  CAS  PubMed  Google Scholar 

  24. Lai R, Medeiros LJ, Coupland R, McCourty A, Brynes RK . Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases Mod Pathol 1998 11: 457–463

    CAS  PubMed  Google Scholar 

  25. Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T . Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer Am J Pathol 1995 146: 1161–1169

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE . Altered expression of the retinoblastoma gene produkt: prognostic indicator in bladder cancer J Natl Cancer Inst 1992 84: 1251–1256

    Article  CAS  PubMed  Google Scholar 

  27. Grierson AJ, Hodgkins MA, Hancock BW, Goepel JR, Royds J, Goyns MH . Investigation of the RB-1 tumour suppressor gene in a United Kingdom series of non-Hodgkin's lymphomas Leuk Lymphoma 1996 23: 353–363

    Article  CAS  PubMed  Google Scholar 

  28. Aguilera NSI, Bijwaard KE, Duncan B, Krafft AE, Chu WS, Abbondanzo SL, Lichy JH, Taubenberger JK . Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas Am J Pathol 1998 153: 1969–1976

    Article  CAS  PubMed  Google Scholar 

  29. Yandell DW, Dryja TP . Detection of sequence polymorphisms by enzymatic amplification and direct genomic sequencing Am J Hum Genet 1989 45: 547–555

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Liu Y, Rasool O, Grandér D, Lindblom A, Einhorn S . Sequence variability of a prolonged tetranucleotide repeat Hum Mol Genet 1995 4: 727–729

    Article  CAS  PubMed  Google Scholar 

  31. Peltomäki P, Aaltonen LA, Sistonen P, Pylkkänen L, Mecklin JP, Jävinen H, Green JS, Jass JR, Weber JL, Leach FS, Pedersen GM, Hamilton SR, de la Chapelle A, Vogelstein B . Genetic mapping of a locus predisposing to human colorectal cancer Science 1993 260: 810–812

    Article  PubMed  Google Scholar 

  32. Cawkwell L, Bell SM, Lewis FA, Dixon MF, Taylor GR, Quirke P . Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology Br J Cancer 1993 67: 1262–1267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Shimizu T, Toguchida J, Kato MV, Kaneko A, Ishizaki K, Sasaki MS . Detection of mutations of the RB1 gene in retinoblastoma patients by using exon-by-exon PCR-SSCP analysis Am J Hum Genet 1994 54: 793–800

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Hogg A, Onadim Z, Baird PN, Cowell JK . Detection of heterozygous mutations in the RB1 gene in retinoblastoma patients using single-strand confirmation polymorphism analysis and polymerase chain reaction sequencing Oncogene 1992 7: 1445–1451

    CAS  PubMed  Google Scholar 

  35. Lohmann DR, Brandt B, Höpping W, Parsarge E, Horsthemke B . Distinct RB1 gene mutations with low penetrance in hereditary retinoblastoma Hum Genet 1994 94: 349–354

    Article  CAS  PubMed  Google Scholar 

  36. Toguchida J, McGee TL, Paterson JC, Eagle JR, Tucker S, Yandell DW, Dryja TP . Complete genomic sequence of the human retinoblastoma susceptibility gene Genomics 1993 17: 535–543

    Article  CAS  PubMed  Google Scholar 

  37. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting J Clin Oncol 1989 7: 1630–1636

    Article  CAS  PubMed  Google Scholar 

  38. Martinez JC, Piris MA, Sanchez-Beato M, Villuendas R, Orradre JL, Algara P, Sanchez-Verde L, Martinez P . Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction J Pathol 1993 169: 405–412

    Article  CAS  PubMed  Google Scholar 

  39. Nguyen PL, Zukerberg LR, Benedict WF, Harris NL . Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma Am J Clin Pathol 1996 105: 538–543

    Article  CAS  PubMed  Google Scholar 

  40. Barrans SL, Haynes A, Fegan C, Jack AS, Morgan GJ . Immunohistochemical analysis of cell proliferation and oncogene expression in nodal diffuse large B-cell lymphoma Br J Haematol 1997 97: 31 (Abstr.)

    Google Scholar 

  41. Geradts J, Andriko JW, Abbondanzo SL . Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas Am J Clin Pathol 1998 109: 669–674

    Article  CAS  PubMed  Google Scholar 

  42. Ballerini P, Gaidano G, Gong JZ, Tassi V, Saglio G, Knowles DM, Dalla-Favera R . Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma Blood 1993 81: 166–176

    CAS  PubMed  Google Scholar 

  43. Krawczak M, Reiss J, Cooper DN . The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences Hum Genet 1992 90: 41–54

    Article  CAS  PubMed  Google Scholar 

  44. Koeberl DD, Bottema CDK, Ketterling RP, Bridge PJ, Lillicrap DP, Sommer SS . Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in a human gene Am J Hum Genet 1990 47: 202–217

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Weide R, Tiemann M, Pflüger K-H, Köppler H, Parvizl B, Wacker H-H, Kreipe HH, Havemann K, Parwaresch MR . Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomas Leukemia 1994 8: 97–101

    CAS  PubMed  Google Scholar 

  46. Hayashi K, Yandell DW . How sensitive is PCR-SSCP? Hum Mutat 1993 2: 338–346

    Article  CAS  PubMed  Google Scholar 

  47. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T . CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene Oncogene 1993 8: 1063–1067

    CAS  PubMed  Google Scholar 

  48. Bartkova J, Lukas J, Strauss M, Bartek J . Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation Oncogene 1998 17: 1027–1037

    Article  CAS  PubMed  Google Scholar 

  49. Petrucci MT, Ariola C, Ricciardi MR, Pisegna S, Fimia GM, Annino L, Testi AM, Lo Coco F, Mandelli F, Tafuri A . Molecular control of cell cycle in normal and neoplastic hemopoiesis: p16, CDK4, and Rb showed a common tumorigenesis pattern in acute lymphoblastic leukemia Blood 1996 88: 120b (Abstr.)

    Google Scholar 

  50. Ando K, Griffin JD . Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells Oncogene 1995 10: 751–755

    CAS  PubMed  Google Scholar 

  51. Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Müller-Hermelink HK, Bentz M, Hiddemann W, Döhner H . Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma Cancer Res 1997 57: 4608–4614

    CAS  PubMed  Google Scholar 

  52. Haas K, Staller P, Geisen C, Bartek J, Eilers M, Möröy T . Mutual requirement of CDK4 and Myc in malignant transformation: evidence for cyclin D1/CDK4 and p16INK4A as upstream regulators of Myc Oncogene 1997 15: 179–192

    Article  CAS  PubMed  Google Scholar 

  53. Li Y, Nichols MA, Shay JW, Xiong Y . Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb Cancer Res 1994 54: 6078–6082

    CAS  PubMed  Google Scholar 

  54. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG . Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53 Proc Natl Acad Sci USA 1998 95: 8858–8863

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ . Tumor induction and tissue atrophy in mice lacking E2F-1 Cell 1996 85: 537–548

    Article  CAS  PubMed  Google Scholar 

  56. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG Jr, Livingston DM, Orkin SH, Greenberg ME . E2F-1 functions in mice to promote apoptosis and suppress proliferation Cell 1996 85: 549–561

    Article  CAS  PubMed  Google Scholar 

  57. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR . Role of E2F-1 in chemosensitivity Cancer Res 1998 58: 4292–4296

    CAS  PubMed  Google Scholar 

  58. Volm M, Koomägi R, Rittgen W . Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma Int J Cancer 1998 79: 294–299

    Article  CAS  PubMed  Google Scholar 

  59. Rabbani F, Richon VM, Orlow I, Lu ML, Drobnjak M, Dudas M, Charytonowicz E, Dalbagni G, Cordon-Cardo C . Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization J Natl Cancer Inst 1999 91: 874–881

    Article  CAS  PubMed  Google Scholar 

  60. Garcia-Sanz R, Gonzalez M, Vargas M, Chillon MC, Balanzategui A, Barbon M, Flores MT, San Miguel JF . Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas Leukemia 1997 11: 1915–1920

    Article  CAS  PubMed  Google Scholar 

  61. Grønbøk K, de Nully Brown P, Ralfkiaer E, Zeuthen J, Guldberg P . Concurrent disruption of the p16-pRb and ARF-p53 pathways predicts poor prognosis in non-Hodgkin's lymphoma Proc Am Assn Cancer Res 1999 40: 282 (Abstr.)

    Google Scholar 

Download references

Acknowledgements

We thank Jan Alsner for kindly providing DNA from retinoblastoma patients with known RB1 mutations. We also appreciate the excellent technical assistance of Marianne Christensen, Maj-Britt S Berg, Lene Nielsen and Bodil Harder. The work was supported in part by the Danish Medical Research Council Grant 9400660.

Author information

Authors and Affiliations

  1. Department of Pathology, University of Southern Denmark – Odense University, Denmark

    MB Møller, PW Kania, O Nielsen & NT Pedersen

  2. Department of Pathology (Neuropathology) and Neurosurgical Service, Molecular Neuro-Oncology Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Y Ino & DN Louis

  3. Department of Clinical Genetics, University of Southern Denmark – Odense University, Denmark

    A-M Gerdes

  4. Department of Immunology and Microbiology, University of Southern Denmark – Odense University, Denmark

    K Skjødt

Authors
  1. MB Møller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. PW Kania
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Ino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A-M Gerdes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. DN Louis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Skjødt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. NT Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Møller, M., Kania, P., Ino, Y. et al. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia 14, 898–904 (2000). https://doi.org/10.1038/sj.leu.2401761

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401761

Keywords

This article is cited by

Search

Advanced search

Quick links